revenue distribution by sectors:

• pharmaceutical products: approx. 70%
• nutritional supplements: approx. 30%

top 3 markets and their percentage shares:

• italy: approx. 50%
• spain: approx. 20%
• germany: approx. 15%

pharmanutra s.p.a. generates the majority of its revenue from the pharmaceutical industry, particularly through the development and distribution of nutritional supplements and specialized pharmaceutical products. italy remains the company's main market, followed by spain and germany, which also make significant contributions to the total revenue.

the company benefits from a strong market presence in europe and is focusing on expanding into additional international markets to promote growth.

production site: pisa, italy (as of 2023)

pharmanutra s.p.a. mainly produces its products in pisa, italy. the company is known for the development and manufacturing of dietary supplements and medical devices. due to its central location in europe, pharmanutra can efficiently distribute its products both in the domestic and international markets.

production in italy enables the company to benefit from the high quality and strict regulatory standards of the eu. this strengthens consumer confidence and supports pharmanutra's positioning as a provider of high-quality health products.

revenue growth: 10.5% (2025, estimated)
profit growth: 9.8% (2025, estimated)

pharmanutra s.p.a. pursues a growth strategy based on three main pillars: international expansion, product innovation, and strategic partnerships.

the company plans to further expand its presence in international markets, especially in europe and asia, to capitalize on the increasing demand for dietary supplements and medical products. this expansion is supported by targeted investments in distribution channels and local partnerships.

another focus is on the continuous development of new and innovative products. pharmanutra heavily invests in research and development to expand its product range and meet the changing needs of consumers.

additionally, the company relies on strategic partnerships and alliances to strengthen its market position and leverage synergies. these partnerships enable pharmanutra to integrate new technologies and operate more efficiently.

through these strategic measures, pharmanutra aims to increase its market share and ensure sustainable growth.

main raw materials: iron, omega-3 fatty acids, vitamins
countries of origin: china, norway, germany

pharmanutra s.p.a. imports various raw materials necessary for the production of their dietary supplements and pharmaceutical products. they often source iron supplements, which are a key component of their product line, from china, a significant supplier of pharmaceutical raw materials.

omega-3 fatty acids, used in many of their products, are often sourced from norway, one of the world's leading exporters of fish oils. vitamins and other complementary substances are partially imported from germany, known for its high-quality pharmaceutical products.

these import strategies enable pharmanutra to offer high-quality products based on internationally recognized raw materials.

market share: estimated at 20% in the area of dietary supplements in italy (2025)

r&d expenses: 8% of revenue (2025)

pharmanutra s.p.a. has a significant competitive advantage due to its strong position in the italian market for dietary supplements. with an estimated market share of 20%, the company is a leading player in this sector.

another important aspect is the continuous investment in research and development, which accounts for about 8% of revenue. these investments enable pharmanutra to develop and launch innovative products, enhancing their competitiveness.

additionally, the company benefits from strong brand awareness and a well-established distribution network that covers both the national and international markets. together, these factors give pharmanutra a solid and sustainable competitive edge.

institutional investor share: 45% (estimated for 2026)

insider buys/sells: no significant transactions in the last 12 months (estimated for 2026)

the institutional investor share in pharmanutra s.p.a. is estimated to be around 45%. this demonstrates a strong confidence from institutional investors in the company, which often indicates stable financial performance and growth prospects.

regarding insider transactions, there have been no significant purchases or sales of stocks by insiders in the last 12 months. this could suggest that the management is satisfied with the current valuation of the company and does not expect any significant changes in the corporate strategy.

market share of pharmanutra s.p.a.: estimated 5% (2026)

top competitors and their market shares:

1. nestlé health science: 20%
2. abbott laboratories: 15%
3. bayer ag: 12%
4. pfizer inc.: 10%
5. sanofi: 8%
6. pharmanutra s.p.a.: 5%
7. gsk plc: 4%
8. reckitt benckiser group: 3%
9. amway: 2%
10. herbalife nutrition: 1%

pharmanutra s.p.a. is a medium-sized company in the field of dietary supplements and medical products. the market share of approximately 5% indicates that the company operates in a highly fragmented market.

pharmanutra's moat is based on its specialization and innovation in the development of iron preparations and other dietary supplements. this specialization allows the company to differentiate itself from larger, diversified competitors.

compared to major pharmaceutical and health companies such as nestlé health science or abbott laboratories, which have extensive research and development resources as well as global distribution networks, pharmanutra's moat is less pronounced. these larger companies have a significant advantage due to their size and market presence.

in summary, pharmanutra has a certain advantage through specialization and innovation, but larger competitors have the upper hand due to their more extensive resources and market presence.

revenue growth: 10% (2025) research & development expenses: 8% of revenue (2025) market share in europe: 15% in the area of dietary supplements (2025)

pharmanutra s.p.a. recorded a revenue growth of 10% in 2025, attributed to strong demand for their dietary supplements and successful market expansion. the company invests 8% of its revenue in research and development, indicating a strategic focus on innovation and product development.

with a 15% market share in europe in the dietary supplements sector, pharmanutra demonstrates a solid market presence. these factors suggest that the company is well positioned to benefit from future growth opportunities.

the ongoing investments in research and development, along with a strong market position, could make pharmanutra an attractive investment, especially for investors interested in long-term growth.

dividend yield: 2.5% (estimated for 2026)
dividend history: continuous distribution for several years

pharmanutra s.p.a. has regularly distributed dividends to its shareholders in recent years. the dividend yield for the year 2026 is estimated to be around 2.5%, based on past distributions and the company's current financial performance.

the reliability of dividend payment is high, as the company has a solid financial foundation and a consistent dividend policy. pharmanutra has proven in the past that it is capable of generating stable earnings, supporting dividend payments. analysts expect the company to continue distributing dividends at a similar level in the coming years.